Overview
Coffin-Lowry syndrome (CLS) is a rare X-linked neurodevelopmental disorder caused by mutations in the RPS6KA3 gene, which encodes the RSK2 protein kinase. A subset of these mutations disrupt normal RNA splicing, resulting in a non-functional or improperly formed protein. This review evaluates the scientific rationale for using antisense oligonucleotides (ASOs) as a precision-medicine strategy to correct specific splicing defects in CLS. While no ASO therapies are currently approved or in clinical development for CLS, precedent in other rare genetic diseases suggests this approach is feasible for select patients.
Coffin-Lowry Syndrome: Molecular Background
CLS is caused by loss-of-function mutations in RPS6KA3, leading to deficiency of the RSK2 kinase. RSK2 plays a key role in the Ras/MAPK signaling pathway, which is critical for neuronal development, learning, memory, and cell survival. Disruption of this pathway is believed to underlie the neurological and developmental features of CLS.
Approximately 20% of known RPS6KA3 mutations are associated with aberrant RNA splicing. These mutations may result in exon skipping, activation of cryptic splice sites, or abnormal intron retention, each of which can severely impair RSK2 protein function.
Therapeutic Rationale: Why ASOs
Antisense oligonucleotides are synthetic, single-stranded nucleic acids designed to bind specific RNA sequences. Depending on their design, ASOs can:
- Promote degradation of mutant mRNA
- Block translation of faulty transcripts
- Modulate pre-mRNA splicing to restore production of a functional protein
For diseases caused by splicing defects, ASOs can be engineered to correct abnormal splicing by:
- Preventing exon skipping
- Promoting exon inclusion
- Blocking cryptic splice sites
This mechanism enables highly targeted intervention without altering the patient’s genome, making ASOs well suited for precision medicine approaches in rare genetic disorders.
Applicability to Coffin-Lowry Syndrome
In CLS patients with splicing-related RPS6KA3 mutations, ASO-based splicing correction represents a biologically plausible therapeutic strategy. By restoring correct splicing of the pre-mRNA, an ASO could enable production of partially or fully functional RSK2 protein.
This approach would be inherently mutation-specific. Each ASO would need to be designed to target a defined splicing error, limiting applicability to subsets of patients rather than the entire CLS population. Nevertheless, the underlying disease mechanism and gene architecture support feasibility in principle.
Precedent in Other Rare Diseases
ASO therapies have successfully translated from concept to clinic in other genetic diseases involving splicing defects, including:
- Spinal muscular atrophy (SMA): An FDA-approved ASO corrects splicing of the SMN2 gene, restoring functional protein production.
- Duchenne muscular dystrophy (DMD): Multiple ASOs are approved to induce exon skipping and partially restore dystrophin expression.
These examples demonstrate that splicing modulation can produce meaningful clinical benefit when the genetic mechanism is well understood and the patient population is molecularly defined.
Development Challenges and Limitations
Despite its promise, ASO-based therapy for CLS faces several challenges:
- Mutation heterogeneity: CLS is caused by a wide range of mutations, requiring multiple ASOs to address different splicing defects.
- Patient identification: Accurate molecular diagnosis is essential to identify patients with actionable splicing mutations.
- Delivery to the central nervous system: Effective and sustained delivery remains a key consideration, though progress in ASO delivery for neurological diseases continues to advance.
At present, there are no FDA-approved ASOs or active clinical trials specifically targeting CLS.
Conclusion
ASO-mediated correction of RNA splicing defects represents a rational and testable therapeutic strategy for a subset of Coffin-Lowry syndrome patients with defined RPS6KA3 splicing mutations. While this approach remains investigational, advances in RNA-targeted medicine and successful precedent in other rare diseases support its potential as a future precision-medicine pathway for CLS.
Technical Appendix: Validation of Splicing Mutations
Identifying Splicing Defects
Determining whether a mutation causes aberrant splicing typically involves a combination of computational prediction and experimental validation.
Bioinformatic prediction:
Advanced algorithms assess the likelihood that a sequence variant disrupts normal splicing. Leading tools include deep-learning–based predictors such as SpliceAI and Pangolin, which are commonly used to prioritize variants for experimental testing.
Experimental validation:
The gold standard method for confirming splicing defects is the minigene splicing assay. This cell-based assay compares wild-type and mutant gene fragments to directly assess splicing outcomes. When patient-derived samples are available, RT-PCR or RNA sequencing can confirm splicing abnormalities in a physiological context.
Together, these approaches enable rigorous identification of CLS patients whose mutations may be amenable to ASO-based splicing correction.
Cori Gorman, PhD, MBA